ezlopitant
Small moleculeexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- Neurokinin 1 receptorANTAGONIST
TACR1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(C(C)C)cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1- Mol. weight
- 454.66 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL515966 ↗
Also known as
- 1-azabicyclo(2.2.2)octan-3-amine, 2-(diphenylmethyl)-n- ((2-methoxy-5-(1-methylethyl)phenyl)methyl)-, (2s-cis)-
- 2-diphenylmethyl-3-(5-isopropyl-2-methoxybenzylamino)-1-azabicyclo(2.2.2)octane
- (2s,3s)-2-(diphenylmethyl)-3-((5-isopropyl-2-methoxy- benzyl)amino)quinuclidine
- (2s,3s,4s)-2-diphenylmethyl-3-(5-isopropyl-2-methoxybenzylamino)-1-azabicyclo(2.2.2)octane
- cj-11974
- cj-11974
- ezlopitant
- ezlopitant
- ezlopitant